VEGF-A antibody Polyclonal Antibodies Primary antibodies
- Known as:
- VEGF-A (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100468
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- VEGF- antibody Polyclonal Antibodies Primary antibodies
Related genes to: VEGF-A antibody Polyclonal Antibodies Primary antibodies
- Gene:
- FLT1 NIH gene
- Name:
- fms related tyrosine kinase 1
- Previous symbol:
- FLT
- Synonyms:
- VEGFR1
- Chromosome:
- 13q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
- Gene:
- FLT4 NIH gene
- Name:
- fms related tyrosine kinase 4
- Previous symbol:
- -
- Synonyms:
- VEGFR3, PCL
- Chromosome:
- 5q35.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-10-25
- Date modifiied:
- 2016-10-05
- Gene:
- KDR NIH gene
- Name:
- kinase insert domain receptor
- Previous symbol:
- -
- Synonyms:
- FLK1, VEGFR, VEGFR2, CD309
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-10
- Date modifiied:
- 2019-04-23
- Gene:
- NRP1 NIH gene
- Name:
- neuropilin 1
- Previous symbol:
- -
- Synonyms:
- NRP, VEGF165R, CD304
- Chromosome:
- 10p11.22
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-23
- Date modifiied:
- 2016-10-05
- Gene:
- NRP2 NIH gene
- Name:
- neuropilin 2
- Previous symbol:
- -
- Synonyms:
- VEGF165R2
- Chromosome:
- 2q33.3
- Locus Type:
- gene with protein product
- Date approved:
- 1998-12-23
- Date modifiied:
- 2015-09-01
Related products to: VEGF-A antibody Polyclonal Antibodies Primary antibodies
Related articles to: VEGF-A antibody Polyclonal Antibodies Primary antibodies
- During the egg laying period of a hen, one pre-hierarchical follicle, approximately 6-8 mm in size, is selected into the preovulatory hierarchy for ovulatory stage development. These follicles develop from white follicles that are 2-5 mm in size. Although numerous studies have investigated follicle selection, the molecular mechanisms underlying pre-hierarchical follicle development and recruitment remain unclear. In this study, we explored the genes regulating chicken ovarian pre-hierarchical follicular development by sequencing RNA from ≤ 2 mm follicles in ovarian stroma (OS), 3-4 mm small white follicles (SWFs), and 6-8 mm small yellow follicles (SYFs) using Oxford Nanopore long-read transcriptome sequencing technology. Herein, we obtained 2,164 differentially expressed transcripts (DETs) from the three phases. The steroidogenesis and angiogenesis signaling pathways were enriched in SWFs compared with in OS. In contrast, the endocytosis, p53, FoxO, and oocyte meiotic signaling pathways were significantly enriched during SYF development compared with during SWF development. The focal adhesion, apelin, and TGF-β signaling pathways were significantly enriched in all three phases. The time-course analysis of DETs and cluster Kyoto Encyclopedia of Genes and Genomes enrichment revealed dynamic changes in gene expression during pre-hierarchical follicle development. Key examples include the genes associated with follicle initial recruitment and development (AMH, GDF9, INHBB, BMPR1B, StAR, and FST), angiogenesis-related genes (ANGPT2, VEGFA, VEGFC, VEGFD, and VEGFRs), extracellular matrix remodeling-related genes (MMP2 and MMP10), and Wnt signaling pathway genes (WNT4, WNT9A, CTNNB1, RSPO3, and WIF1). Moreover, RSPO3 upregulated the expression of FSHR and StAR in cultured chicken Pre-hierarchical follicle granulosa cells and activated the Wnt signaling pathway. The results obtained in this study demonstrate the transcriptional dynamics during small folliculogenesis; the identified signaling pathways and DETs can be used as candidate targets for investigating pre-hierarchical follicle development in chickens. - Source: PubMed
Publication date: 2026/02/18
Cao XiaoyunXu WentingZhang HongruiZhang JialeJiang YunliangLi XianyaoKang Li - The placenta is a highly vascularised organ that depends on tightly regulated angiolymphatic networks to sustain normal fetal growth and maternal adaptation to pregnancy. Disruption of these pathways contributes to major obstetric complications, including preeclampsia, fetal growth restriction, gestational diabetes, and stillbirth. In recent years, advances in molecular pathology and high-throughput technologies have identified a spectrum of angiogenic, lymphangiogenic, and endothelial biomarkers that provide mechanistic insights and hold translational promise. Among these, vascular endothelial growth factors (VEGF-A, VEGF-C, VEGF-D), placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), angiopoietins, podoplanin, and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) have emerged as key regulators. Differential expression of these markers in placental tissue, maternal circulation, and extracellular vesicles has been correlated with disease severity, placental morphology, and adverse neonatal outcomes. Despite growing evidence, clinical application is limited by methodological heterogeneity, gestational age-specific variability, and incomplete understanding of lymphatic involvement in placental physiology. This review synthesises current knowledge on angiolymphatic biomarkers in the placenta, highlighting their role in vascular development, disease pathogenesis, and potential as diagnostic and prognostic tools. Future research integrating molecular assays, imaging modalities, and systems biology approaches is essential to standardise biomarker panels and translate them into clinically meaningful strategies for maternal-fetal medicine. - Source: PubMed
Publication date: 2025/12/09
Palo SeetuMangla MishuMotwani Rohini - Aberrant activation of proangiogenic signaling pathways, particularly the vascular endothelial growth factor (VEGF) axis, drives neovascularization and tumor progression in colorectal cancer (CRC). Bevacizumab targets VEGF-A-mediated angiogenesis, but the lack of validated predictive biomarkers limits personalized treatment. In this prospective study, we evaluated a panel of circulating angiogenic biomarkers combined with clinical parameters, using mathematical models to predict survival in metastatic CRC patients treated with bevacizumab and chemotherapy. Low VEGF-A and VEGF-D levels, together with high bFGF, were associated with improved overall survival (OS). A logistic regression model incorporating these biomarkers, regional lymph node invasion, and primary tumor resection status showed significant prognostic accuracy ( < 0.001). Incorporating CypA further refined the model, identifying patients with low VEGF-A, VEGF-D, and CypA, and high VEGF-C and PlGF, as having the most favorable OS. These findings demonstrate that integrating clinical and circulating biomarker data can improve individualized risk assessment and support personalized therapeutic strategies for CRC patients receiving bevacizumab. - Source: PubMed
Publication date: 2025/09/24
Moisuc Diana CorneliaMarinca Mihai VasileGafton BogdanConstantinescu DanielaCianga PetruPavel-Tanasa Mariana - Ankylosing spondylitis (AS) is a chronic autoimmune inflammatory disorder predominantly involving the axial skeleton. Understanding the cytokine and chemokine signatures in AS is crucial for elucidating disease mechanisms and identifying potential diagnostic biomarkers. - Source: PubMed
Li HuanWang TingLi MingzeSu WeiLv YingXiao JialingGuo XiaoxinDong KaiGan ChengziZhu JingGong Bo - The primary goal in the management of neovascular age-related macular degeneration (nAMD) is to optimise visual acuity outcomes for patients. Landmark clinical trials have demonstrated improved visual outcomes with standard-of-care vascular endothelial growth factor (VEGF) inhibitors, principally targeting a single ligand (VEGF-A). However, in the real-world setting, not all patients attain optimal visual outcomes with these monotherapies. The role of the VEGF-A and VEGF receptor (VEGFR)-2 axis in angiogenesis and vascular permeability is well characterised, but other VEGF family members, including VEGF-C and VEGF-D, which activate VEGFR-2 and VEGFR-3, have also been implicated in nAMD pathogenesis. This may explain the heterogeneous responses observed with current therapies that primarily inhibit VEGF-A signalling, and in patients who continue to lose vision despite treatment, the consequences can be profound. Vision loss affects daily living and can lead to increased cost of care and susceptibility to falls and injuries. This review will explore the VEGF family of ligands and receptors and their role in nAMD, as well as novel therapeutics in development that target mediators beyond VEGF-A with the potential to provide improved vision benefits to patients. In particular, sozinibercept, an investigational trap biologic inhibitor of VEGF-C and VEGF-D ligands, has shown promising efficacy with superior vision gains when used in combination with ranibizumab dosed monthly (standard-of-care therapy) vs. standard-of-care alone (i.e. monthly ranibizumab). This adds to the increasing evidence that multifaceted approaches that target the VEGF family beyond VEGF-A have the potential to provide better vision outcomes for patients with nAMD. - Source: PubMed
Publication date: 2025/10/11
Khanani Arshad MBakri Sophie JRegillo CarlWeng Christina YWong Tien YBaldwin Megan EHan John JLeitch Ian M